// App-Quantinova.ai

AB0550 (2021) : EFFICACY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND A LOW OR HIGH SWOLLEN JOINT COUNT: A SUBGROUP ANALYSIS OF 2 PHASE 3 STUDIES (SELECT-PsA 1 AND SELECT-PsA 2)

Researchers

Presenter

  • L. Gossec

Principal Investigators

  • D. D. Gladman

  • E. Mcdearmon-Blondell

  • P. Sewerin

  • C. T. Ritchlin

  • D. Feng

  • A. Lertratanakul

  • R. Ranza

  • L. S. Tam

  • A. Marchesoni

  • L. C. Coates

  • P. Nash

Medical Centers

  • Sorbonne Université, Rheumatology, Paris, France

  • AP-HP, Hopital Pitie Salpetriere Rheumatology Department, Paris, France

  • Toronto Western, University of Toronto, Rheumatology, Toronto, Canada

  • AbbVie Inc, Immunology, Illinois, United States of America

  • University of Rochester Medical Center, Rheumatology, Rochester, New York, United States of America

  • Hospital de Clinicas, Universidade Federal de Uberlândia, Rheumatology, Uberlândia, Minas Gerais, Brazil

  • The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China

  • ASST Gaetano Pini-CTO, Dept. of Rheumatology, Milano, Italy

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Griffith University, School of Medicine, Brisbane, Australia

Locations

  • France

  • Canada

  • United States

  • Germany

  • Brazil

  • China

  • Italy

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • Plasminogen Activator, Urokinase

  • Malondialdehyde

  • Albumin/creatinine

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved